I was provided this link from Eric Chung, Respiratory Therapy Professional Practise Lead at Eagle Ridge Hospital which easily illustrates the available services in BC for Pulmonary Rehab and Lung Education.

The map is interactice and provides addresses and contact information.

Thanks Eric!

This educational series on combination therapy for asthma and COPD examines recent evidence and strategies for combining bronchodilators and inhaled corticosteroids in the management of asthma or COPD. The expert faculty will assess clinical data and provide insights on how they may translate to clinical practice in Canada.

Access site HERE

Related articles across the web

• Updated Treatment Guidelines for Type 2 Diabetes
• COPD Could be the Third Leading Cause of Death by 2030

OSA case study PowerPoint

OSA case study PowerPoint

Published on Jun 5, 2015

An attempted summary of the important trials in Critical Care Medicine since 2002. Sepsis. ARDS. Glucose Control. Timing of tracheostomy. Others.

View Presentation HERE

In patients with chronic obstructive pulmonary disorder (COPD), inflammatory changes impact their ability to breathe properly. Patients will eventually retain carbon dioxide (CO₂) as their efforts to maintain normal CO₂levels proves difficult. Experts have long debated whether chronically elevated carbon dioxide levels affect how a patient handles oxygen. As a result, a theory developed that administering oxygen obliterated the drive to breathe.

The problem with the Hypoxic Drive Theory is that it’s a myth concocted on incomplete evidence and often elicits a controversial response, according to John Bottrell, RT, Spectrum Health Ludington Hospital, and COPD/asthma expert for healthcentral.com.

For hypoxemic patients with COPD, most medical experts now recommend administering the lowest amount of oxygen needed to maintain SpO₂ of 88% to 92%, according to Bottrell.

Full Story

Ten thousand people suffering from cystic fibrosis have been offered new hope after a gene therapy was shown to reverse the condition in some cases.

The therapy, which was described by health experts as ‘life-changing’ is likely to be available within the next five years following a landmark trial.

Inhaler Device Chart

Fees

Fees include online learning components and course materials.

• Education for Chronic Disease: $625.00
• COPD: $625.00 (with option at time of registration to purchase the Bourbeau textbook for an additional $60)
• Asthma: $625.00
• Spirometry: $550.00

CCCEP: The Education, COPD and Asthma courses have been accredited by Canadian Council on Continuing Education in Pharmacy. Pharmacists have been involved in development of the curricula and review of the content.

The Canadian Council on Continuing Education in Pharmacy has confirmed accreditation as follows:

• Education Course – 6.5 CEUs
• COPD Course – 13.00 CEUs
• Asthma Course – 6.5 CEUs

Resptrec Courses